Sandalwood giant can smell big dollars in warts more

ViroXis Corporation Announces expanded board of directors and advisors more

ITClamp Hemorrhage Control System from Innovative Trauma Care more

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts more

Vidacare Corp. aims to ease that pain with the OnControl Bone Marrow System. The Bronze winner of The Wall Street Journal's Technology Innovation Awards, and winner of the Medical-Devices category, the product allows doctors to more quickly and precisely take samples from inside the bone more

DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. more

Innovative Trauma Care (ITC) has received regulatory approval from Health Canada for commercial sale of its first product, the IT Clamp™ more

BiO2 Medical, Inc and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding more

ENTrigue Surgical Announces Sinus Surgery Collaboration with fiagon GmbH more

Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC Technology for Protein Formulation more

Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division more

BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication more

NMP Neuwirth Medical Products GmbH signs an exclusive distribution partnership for the Ventera, MediENT, ENTact, Synaero, and SerpENT in Germany

ENTrigue Surgical participates in the first Global Update on FESS, The Sinuses, and The Nose in Vienna, Austria

BiO2 Medical Announces First in Man Clinical Study more

BiO2 Medical Secures Series B Round Funding.

BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently completed its $13.7M Series B round of funding, which included the conversion of a $1M State of Texas Emerging Technology Fund (ETF) award. The round was led by San Antonio's Targeted Technology Fund and BiO2 Medical's investment bankers, Pasadera Capital.

This important milestone has allowed the company to complete Design Verification Testing in support of CE Mark submission, initiate a first in human clinical study in Medellin, Colombia, and conduct a Pre-IDE Meeting with FDA.

As stated by Christopher E. Banas, BiO2 Medical's Chairman and Chief Executive Officer, "This Series B funding has been instrumental to the recent successes of BiO2 Medical, and specifically the Angel™ Catheter program. With CE Mark approval anticipated in Q1/2 2012, the first in human clinical study underway, and a clear regulatory pathway defined in the US, BiO2 Medical is well on its way to commercializing the Angel™ Catheter worldwide which will help protect critically ill patients from hospital acquired PE."

BiO2 Medical's Angel™ Catheter, named after its inventor and BiO2 Medical's Chief Medical Officer, Dr. Luis F. Angel, is a central venous catheter and Inferior Vena Cava (IVC) filter combination device, intended to protect against potentially fatal Pulmonary Embolism (PE) in critically ill patients. The Angel™ Catheter will include a first of its kind prophylactic indication for IVC filter use.

For more information regarding BiO2 Medical and the Angel™ Catheter, please visit www.bio2medical.com back

Study Finds Intraosseous Infusion is Equivalent to Intravenous Infusion During Therapeutic Hypothermia more

Vidacare Corporation to Sponsor 2012 British Journal of Nursing Haematology Award Category more